Search results
COVID-flu combo vaccine shows ‘positive’ results in phase 3 trials, Moderna says: A 'two-for' option
Fox News via Yahoo News· 7 days agoModerna, which is developing a combination COVID-flu vaccine, announced on Monday that in phase 3...
Moderna’s New Flu-COVID Combi mRNA Vaccine Outperforms Separate Shots In Trials
IFLScience· 6 days agoThe data are yet to be submitted for publication in a peer-reviewed journal, but the company says...
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
Investor's Business Daily· 7 days agoMock said Moderna used a new antigen in its updated Covid vaccine to help focus on newer strains....
Moderna’s COVID, flu combination vaccine shows stronger immune response, company announces
WSOC-TV Charlotte· 7 days agoModerna is working on a single vaccine that it says will protect people against both COVID-19 and...
Moderna's mRNA-1283 vaccine shows promise in Phase 3 trial By Investing.com
Investing.com· 4 days agoModerna , Inc. (NASDAQ:MRNA) has announced successful results from the Phase 3 trial of its...
Moderna to present combo COVID-flu vaccine to regulators after trial
Scripps News via AOL· 7 days agoModerna also said mRNA-1083 had "an acceptable tolerability and safety profile." The shots had...
Moderna says its combination COVID and flu vaccine tested better than separate shots
CBS News· 7 days agoModerna announced Monday that its combination COVID and flu vaccine showed positive results in a...
Moderna’s Covid-19 vaccine meets primary efficacy endpoint in Phase III trial
Clinical Trials Arena via Yahoo Finance· 3 days agoModerna has announced that its Phase III clinical trial of the investigational next-generation...
COVID summer guide: How to navigate symptoms, variants and vaccines this season
Yahoo Life· 4 days agoThat doesn’t mean everyone has to stay home, simply that you should know your risks and do what you...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation...
The Kansas City Star· 4 days agomRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older